Obrixtamig

7 月 15 日，勃林格殷格翰发布 2026 年上半年财报。报告期内，勃林格殷格翰净销售额增长 16.2%，达到 158 亿欧元。其中，人用药品业务贡献 131 亿欧元，动物保健业务贡献 26 亿欧元。 来源：企业官网 上半年，在新产品上市的推动下，人用药品销售额增长 20.1%，达到 131 亿欧元。成熟产品恩格列净（用于治疗慢性肾病、2 型糖尿病和心力衰竭的）仍然是主要的增长动力，上半年净销售额达 57 亿欧元。恩格列净的增长得益于其庞大且不断增长的患者群体，以及美国定价和报销环境的变化，这些因素共同推动了销量的显著增长。 勃林格殷格翰最新推出的产品那米司特和宗艾替尼也取得了成功，尤其是在美国。 那米司特用于治疗特发性肺纤维化（IPF）和进行性肺纤维化（PPF），其强劲的市场表现反映了该疾病领域对新治疗方案的迫切需求，因为多年来该领域的治疗进展有限。继在美国、中国、日本、泰国、阿联酋、英国和巴西获得批准后，那米司特正在等待欧洲药品管理局（EMA）的批准。 宗艾替尼是用于治疗 HER2 突变型晚期非小细胞肺癌的口服药物。该药已在美国、中国和日本成功上市，这也标志着勃林格殷格翰时隔十年重返肿瘤领域。勃林格殷格翰预计，宗艾替尼要到 2028 年 III 期数据公布后，才会在欧洲上市。 2026 年上半年，勃林格殷格翰继续推进其后期研发管线项目，并在肿瘤和心肾代谢疾病领域取得了显著进展。其中，GLP1R/GCGR 双激动剂 Survodutide 的 III 期临床试验取得积极数据，表明该药物除了治疗超重和肥胖外，还具有改善代谢和肝脏健康的潜力。 与此同时，勃林格殷格翰启动了三项 III 期肿瘤学临床试验，进一步强化其拓展精准肿瘤治疗的目标。此外，其还推进了多项重点资产，包括在研癌症免疫疗法 Obrixtamig，以及靶向肾脏疾病的在研药物 Apecotrep。勃林格殷格翰有 5 个新化合物进入临床试验，目前人用药品研发管线涵盖约 80 个项目。 编辑：馨药 封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。

Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for survodutide and pipeline progress strengthen long-term outlook Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the U.S. due to increased demand for JARDIANCE® (empagliflozin) and successful new launches. Group net sales increased by 16.2%* to EUR 15.8 billion, with Human Pharma contributing EUR 13.1 billion and Animal Health EUR 2.6 billion. Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim said: “The strong uptake of our new products JASCAYD® and HERNEXEOS® show the value of the scientific innovation behind these medicines for patients, bringing real progress in areas with significant unmet medical need. In an era of accelerated medical discovery, where the boundaries of what is possible are continuously expanding, innovation-friendly environments such as the United States play a critical role in ensuring new therapies reach patients more rapidly.” Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: “Our business results show that, in Human Pharma and Animal Health, we successfully navigated a challenging macroeconomic environment and political uncertainties. We remain focused on delivering innovative medicines to patients and animals worldwide. Looking ahead, we need to direct our long-term investments to where they are closest to our growth markets and where they can create the best possible impact for patients. This also includes engaging with governments around the globe to create an environment that appropriately recognizes the value of innovative medicines and ensures patient access.” Human Pharma: Growth supported by key launches Human Pharma sales grew 20.1%* to EUR 13.1 billion, supported by the new product launches. Established products such as JARDIANCE® for the treatment of chronic kidney disease, type 2 diabetes and heart failure remained major growth drivers, contributing EUR 5.7 billion in net sales in the first half of the year. The positive development of JARDIANCE® was supported by a large and growing patient base, as well as changes in the U.S. pricing and reimbursement environment, which drove significant volume growth. This trend is in line with Boehringer’s commitment to ensuring continued patient access and affordability. Without the JARDIANCE® volume effect, the growth of the Human Pharma Business Unit in the first six months would have been in line with the overall pharma market. The company also saw a successful uptake of its most recent product launches, JASCAYD® (nerandomilast) and HERNEXEOS® (zongertinib), particularly in the U.S., as both medicines were able to gain significant traction thanks to the innovation-friendly climate in the U.S. but also in China and Japan. Streamlined processes as well as stronger incentives for innovation in these geographies paved the way for swiftly making these breakthrough medicines available to patients. JASCAYD®, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), saw a strong uptake reflecting the urgent need for new treatment options in a disease area that has seen limited therapeutic progress for many years. Following approvals in the United States, China and Japan, as well as Thailand, the United Arab Emirates, the UK and Brazil, JASCAYD® is awaiting EU approval from the European Medicines Agency (EMA). HERNEXEOS®, an oral treatment for HER2-mutant advanced non-small cell lung cancer, marked the company’s successful re-entry into oncology after ten years with launches in the U.S., China and Japan. The company expects that HERNEXEOS® will be available for European patients only from 2028 after Phase III data becomes available. Boehringer continued to advance its late-stage pipeline programs during the first half of 2026, realizing significant progress in oncology and cardio-renal-metabolic diseases. Positive Phase III data for survodutide demonstrated the medicine’s potential to address metabolic and liver health in addition to overweight and obesity. Progress with a next-generation triple agonist underlines Boehringer’s ambition to build a broad obesity and metabolic health portfolio. At the same time, Boehringer Ingelheim initiated three Phase III oncology trials, reinforcing its goal to expand precision cancer care. The company also advanced key assets such as obrixtamig, an experimental cancer immunotherapy, and apecotrep, an investigational drug targeting kidney disease. Research momentum also continued to be strong, with five new compounds entering clinical trials. The Boehringer Human Pharma R&D pipeline spans around 80 projects. Animal Health: Focus on new launches and emerging disease outbreaks response The Animal Health business reported net sales of EUR 2.6 billion in the first six months of 2026, a 0.4%* increase compared to the previous year. The performance reflected a modestly growing animal health market, with increased consumer price sensitivity and fewer veterinary visits in several countries. The company continues to execute its 2026 launch plan, including LENZELTA®, a new vaccine that advances mastitis prevention in dairy cows and has launched in several EU countries, and Eko Vet+™ | CANINEBEAT® AI, an AI-based solution that helps detect heart murmurs in dogs and has already launched in the U.S., the UK and Germany. Boehringer Ingelheim also continues to support responses to emerging animal disease outbreaks, including New World screwworm in the U.S., after receiving Emergency Use Authorizations (EUAs) earlier this year from the U.S. Food and Drug Administration. The company continues to progress its R&D pipeline in Animal Health, with strong candidates across infectious and non-infectious diseases as well as parasiticides, building a solid innovation foundation for the future in pets, equine, and livestock animals. Outlook Looking ahead, Boehringer expects that uptake of recent launches, upcoming pipeline milestones, and ongoing investments in innovation will support performance for the remainder of the year and beyond. At the same time, the company will remain focused on navigating a dynamic external environment while maintaining a balanced and disciplined approach to growth. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at .